These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 21608370

  • 1. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E, Musialik J, Suchecka W, Petelenz M, Hartman M, Lichtański P, Błońska-Fajfrowska B.
    Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

  • 4. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.
    Przegl Lek; 2011 Apr; 68(6):311-5. PubMed ID: 22039668
    [Abstract] [Full Text] [Related]

  • 5. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
    Verma P, Dayal S, Jain VK, Amrani A.
    J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T, Farkas A, Tolvaj G, Horváth G.
    Orv Hetil; 2006 Feb 19; 147(7):321-4. PubMed ID: 17489160
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Pegylated intereferon hematological safety in comparison with standard].
    Fazylov VKh, Manapova ÉR, Tkacheva SV, Sozinova IuM.
    Eksp Klin Gastroenterol; 2012 Feb 19; (6):96-9. PubMed ID: 23402198
    [Abstract] [Full Text] [Related]

  • 12. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y, Kanto H, Itoh M.
    J Dermatol; 2007 Aug 19; 34(8):577-82. PubMed ID: 17683392
    [Abstract] [Full Text] [Related]

  • 13. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.
    J Viral Hepat; 2009 Mar 19; 16(3):168-77. PubMed ID: 19175874
    [Abstract] [Full Text] [Related]

  • 14. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
    Goto T, Ohshima S, Miura K, Shibuya T, Sato W, Dohmen T, Kamada K, Kanata R, Sakai T, Chiba M, Sugimoto Y, Minami S, Ohnishi H.
    Intern Med; 2013 Mar 19; 52(18):2057-60. PubMed ID: 24042512
    [Abstract] [Full Text] [Related]

  • 15. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S, Avasthi A, Grover S, Chawla YK.
    J Psychosom Res; 2014 Aug 19; 77(2):109-15. PubMed ID: 25077851
    [Abstract] [Full Text] [Related]

  • 16. Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients.
    Ali S, Nazir G, Khan SA, Iram S, Fatima F.
    J Ayub Med Coll Abbottabad; 2010 Aug 19; 22(4):127-30. PubMed ID: 22455279
    [Abstract] [Full Text] [Related]

  • 17. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL, Swiss Association for the Study of the Liver (SASL).
    J Viral Hepat; 2006 Jul 19; 13(7):457-65. PubMed ID: 16792539
    [Abstract] [Full Text] [Related]

  • 18. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C, Pérez-Álvarez R.
    Arch Soc Esp Oftalmol; 2011 Jun 19; 86(6):193-5. PubMed ID: 21767697
    [Abstract] [Full Text] [Related]

  • 19. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y, Ikeda F, Yamamoto K.
    Nihon Rinsho; 2011 May 19; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin--a multi-center study.
    Słuzewski W, Kowala-Piaskowska A, Wysocki J, Figlerowicz M, Gorczyca A, Halota W, Jóźwiak H, Mizerski J, Mozer-Lisewska I, Pawłowska M, Rokitka M, Strawińska E, Szamotulska K.
    Acta Pol Pharm; 2012 May 19; 69(2):319-26. PubMed ID: 22568047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.